Clinical Trials Logo

Chemotherapy clinical trials

View clinical trials related to Chemotherapy.

Filter by:

NCT ID: NCT06202781 Recruiting - Gastric Cancer Clinical Trials

Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and Chemotherapy

Start date: July 1, 2022
Phase:
Study type: Observational

The goal of this study is to analyze the tumor microenvironment (TME) in gastric cancer patients treated with combined immunotherapy and chemotherapy. The main questions it aims to answer are: - Provide profiles of TME between pre-treatment and post-treatment to gain insights into the mechanisms of immunotherapy combined with chemotherapy in advanced gastric cancer - Investigate the crucial factors affecting treatment efficacy by comparing gastric cancer patients with varying treatment responses

NCT ID: NCT06201663 Recruiting - Clinical trials for Chemotherapy-induced Thrombocytopenia

Romiplostim in Chemotherapy-Induced Thrombocytopenia

Start date: December 17, 2023
Phase: Phase 3
Study type: Interventional

Prospective interventional randomized controlled trial to assess safety and efficacy of romiplostim in chemotherapy-induced thrombocytopenia in children and adolescents with solid malignancy

NCT ID: NCT06186479 Recruiting - Clinical trials for Chemotherapy-induced Polyneuropathy

Clinical Trial With Aconite Pain Oil in Oncology Patients Under Chemotherapy to Prevent CIPN Grade-II, to Reduce Symptoms and to Improve the Quality of Life of Patients With CIPN

Start date: March 13, 2024
Phase: Phase 3
Study type: Interventional

The clinical trial is planned as a prospective, multicentre, blinded, randomised, placebo-controlled, national clinical trial in Germany. The clinical trial is designed for testing the prophylactic and therapeutic effects of Aconite pain oil as compared to placebo in oncological patients receiving neurotoxic chemotherapy with taxanes and/or platinum derivatives.

NCT ID: NCT06168032 Recruiting - Lung Cancer Clinical Trials

COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research

Start date: December 8, 2023
Phase: N/A
Study type: Interventional

A prospective, open-label and parallel non-randomized control trial and biomarker research study is intended to compare incidence of repeated COVID-19 infection, severe pneumonitis and mortality between lung cancer patients undergoing systemic antitumor therapies who get vaccinated with 1 booster dose(majorly against XBB) and those who refuse. Meanwhile, a biomarker research is designed to monitor serum level dynamics of specific antibodies against COVID-19,analyze its correlation with incidence of breakthrough infection and further explore optimal periods for vaccination.

NCT ID: NCT06162403 Recruiting - Clinical trials for Chemotherapy-induced Peripheral Neuropathy

Exploring the Benefit of Peripheral Nerve Stimulation in Treating Pain From Chemo-induced Peripheral Neuropathy: A Longitudinal Single Center Feasibility Study

Start date: February 22, 2024
Phase: N/A
Study type: Interventional

To learn if peripheral nerve stimulation (PNS) can help to improve pain in participants with CIPN.

NCT ID: NCT06139458 Recruiting - Gynecologic Cancer Clinical Trials

Cryocompression to Reduce Chemotherapy-induced Peripheral Neuropathy in Gynecologic Cancer - COHORT 2

Start date: January 18, 2024
Phase: N/A
Study type: Interventional

The investigators aim to determine the effect of cryotherapy wraps plus compression therapy (henceforth referred to as cryocompression) versus cryotherapy wraps alone on the incidence and degree of chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer using a noninferiority design. The investigators also aim to determine the effect of cryocompression versus cryotherapy on patient tolerability and patient and staff satisfaction.

NCT ID: NCT06132776 Recruiting - Clinical trials for Chemotherapy-induced Peripheral Neuropathy

The Mamma HiToP Study

Start date: November 3, 2023
Phase: N/A
Study type: Interventional

The HiToP ® 191 PNP an certified device licensed for the treatment of neuropathia. The home-based treatment is to be performed only in accordance with the approved Investigational Plan (CIP) on subjects who have signed an informed consent form. Device use is limited to the approved study investigators. The study is multicenter, randomized, double-blind, and placebo-controlled. Primary Objective: Comparison of the change of paresthesias from baseline until end of therapy between the two patient groups, assessed by questionnaires Secondary Objectives: Further symptoms of neuropathy as well as on health-related quality of life.

NCT ID: NCT06125262 Recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

Trajectory Analysis of NLR and Its Association With Efficacy of Immunochemotherapy in ESCC.

Start date: November 1, 2022
Phase:
Study type: Observational

Conduct a retrospective and prospective study to confirm the association between blood cells counts and the efficacy and safety in immunochemotherapy in patients with advanced esophageal cancer.

NCT ID: NCT06120764 Recruiting - Pediatric Cancer Clinical Trials

Effect of Guided Imagery on Chemotherapy-related Nausea and Vomiting

Start date: November 5, 2023
Phase: N/A
Study type: Interventional

The goal of this randomized controlled study is to assess the effect of guided imagery on chemotherapy-related nausea and vomiting in pediatric hematology-oncology patients. Participants will receive either guided imagery+routine care or routine care. The researchers will compare nausea and vomiting and vital signs between groups.

NCT ID: NCT06065722 Recruiting - Clinical trials for Chemotherapy Induced Nausea and Vomiting

Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy

Start date: September 9, 2023
Phase: Phase 2
Study type: Interventional

The purpose of the proposed study is to provide a clinical approach to chemotherapy induced nausea and vomiting (CINV) prophylaxis in cycle 2 of moderately emetogenic chemotherapy or highly emetogenic chemotherapy for patients who developed breakthrough CINV after cycle 1 based on the available data in the literature as well as the recommendations provided by established guidelines